Changchun High-Tech Industry (SHE:000661) obtained the approval of China's National Medical Products Administration for the clinical trial application of GenSci140 for injection, according to a Shenzhen bourse filing on Saturday.
The Chinese biopharmaceutical product manufacturer's shares fell less than 2% during Monday's morning trade.
The drug is being developed as a treatment for patients with advanced or metastatic solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments